<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Eledon Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc</link>
<description>Latest news and press releases for Eledon Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Mar 2026 21:10:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/eledon-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683562b678dffbe2df0eef2c.webp</url>
<title>Eledon Pharmaceuticals Inc</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc</link>
</image>
<item>
<title>Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-operating-and-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-operating-and-financial-results</guid>
<pubDate>Thu, 19 Mar 2026 21:10:00 GMT</pubDate>
<description>Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continues to support the favorable safety and tolerability profile of tegoprubart Tegoprubart granted Orphan Drug designation by the FDA for the prevention of allograft rejection in liver transplantation IRVINE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmac</description>
</item>
<item>
<title>Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-announces-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-uchicago-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-announces-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-uchicago-medicine</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months - 100% insulin independence achieved in 10 patients who are</description>
</item>
<item>
<title>Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-announces-orphan-drug-designation-granted-to-tegoprubart-for-the-prevention-of-allograft-rejection-in-liver-transplantation</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-announces-orphan-drug-designation-granted-to-tegoprubart-for-the-prevention-of-allograft-rejection-in-liver-transplantation</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug</description>
</item>
<item>
<title>NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/newcelx-announces-strategic-collaboration-with-eledon-pharmaceuticals-to-advance-ncel-101-program-for-type-1-diabetes-1</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/newcelx-announces-strategic-collaboration-with-eledon-pharmaceuticals-to-advance-ncel-101-program-for-type-1-diabetes-1</guid>
<pubDate>Mon, 09 Mar 2026 11:00:00 GMT</pubDate>
<description>NewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN), a clinical-stage immunology company with a focus on transplant medicine.</description>
</item>
<item>
<title>Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-to-participate-in-leerink-partners-2026-global-healthcare-conference-116</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-to-participate-in-leerink-partners-2026-global-healthcare-conference-116</guid>
<pubDate>Wed, 04 Mar 2026 21:05:00 GMT</pubDate>
<description>IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the upcoming Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET (10:40 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay</description>
</item>
<item>
<title>Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-participate-guggenheim-emerging-211000465</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-participate-guggenheim-emerging-211000465</guid>
<pubDate>Thu, 05 Feb 2026 21:10:00 GMT</pubDate>
<description>IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:00 a.m. ET (7:00 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company’s</description>
</item>
<item>
<title>Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-presents-long-term-120000037</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-presents-long-term-120000037</guid>
<pubDate>Fri, 23 Jan 2026 12:00:00 GMT</pubDate>
<description>Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplanta</description>
</item>
<item>
<title>Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-highlights-recent-business-210500837</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-highlights-recent-business-210500837</guid>
<pubDate>Thu, 08 Jan 2026 21:05:00 GMT</pubDate>
<description>Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive preliminary results from first six patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Tegoprubart continues to be used as key component of immunosuppression regimen in xenotransplants, including three transplants of a genetically modified p</description>
</item>
<item>
<title>Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-participate-37th-annual-120000593</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-participate-37th-annual-120000593</guid>
<pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
<description>IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate in a fireside chat at the upcoming 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company’s website u</description>
</item>
<item>
<title>Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-reports-preliminary-data-first-210500877</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-reports-preliminary-data-first-210500877</guid>
<pubDate>Tue, 18 Nov 2025 21:05:00 GMT</pubDate>
<description>IRVINE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine’s Transplant Institute and presented at the Rachmiel Levine-Arthur Riggs Diabetes Research Symposium, held November 14-17, 2025 at City of Hope in Los Angeles, California. The ongoing trial, which has been extended to include a total of 12 subjects, is evaluating tegoprubar</description>
</item>
<item>
<title>Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-announces-recent-business-220000898</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-announces-recent-business-220000898</guid>
<pubDate>Fri, 14 Nov 2025 22:00:00 GMT</pubDate>
<description>Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Data supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Strengthened balance sheet with $57.5 million financing to advance transplantation programs IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals,</description>
</item>
<item>
<title>Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-announces-pricing-50-125600031</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-announces-pricing-50-125600031</guid>
<pubDate>Wed, 12 Nov 2025 12:56:00 GMT</pubDate>
<description>IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares of its common stock at a public offering price of $1.65 per share and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 15,151,515 shares of common stock at a public offering price of $1.649 per pre-funded warrant. The pre-funded warrants will be imm</description>
</item>
<item>
<title>Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-announces-proposed-underwritten-222600975</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-announces-proposed-underwritten-222600975</guid>
<pubDate>Tue, 11 Nov 2025 22:26:00 GMT</pubDate>
<description>IRVINE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants in the proposed offering will be offered by Eledon. In addition, Eledon intends to grant the underwriters a 30-day option to purchase up to a</description>
</item>
<item>
<title>Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-presents-phase-2-bestow-233000282</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-presents-phase-2-bestow-233000282</guid>
<pubDate>Thu, 06 Nov 2025 23:30:00 GMT</pubDate>
<description>Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Confe</description>
</item>
<item>
<title>Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-present-guggenheim-second-120000474</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-present-guggenheim-second-120000474</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will present at the upcoming Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025, at 10:30 a.m. ET (7:30 a.m. PT). To register in advance for the webcast, sign up here. A webcast replay will be accessible following the live session on the Company’s website under Events. About Eled</description>
</item>
<item>
<title>Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-present-results-phase-110000621</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-present-results-phase-110000621</guid>
<pubDate>Fri, 17 Oct 2025 11:00:00 GMT</pubDate>
<description>Conference call and webcast to discuss results to be held on November 7, 2025 at 8:00 a.m. ETIRVINE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the American Society of Nephrology’s upcoming Kidney Week 2025 Annual Meeting taking place in Houston, TX, from November 5-8, 2025. The oral presentation will highlight topline results from the Phase 2 BESTOW trial evaluating tegoprubart for the</description>
</item>
<item>
<title>Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-present-18th-congress-200500909</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-present-18th-congress-200500909</guid>
<pubDate>Wed, 24 Sep 2025 20:05:00 GMT</pubDate>
<description>IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upcoming 18th Congress of the International Xenotransplantation Association (IXA) taking place from September 30–October 3, 2025, in Geneva, Switzerland. Details are as follows: Plenary Session: Immunosuppression, Immune Monitoring, Anti-CD154* Pathway Blockade: How</description>
</item>
<item>
<title>Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-participate-cantor-global-110000276</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-participate-cantor-global-110000276</guid>
<pubDate>Fri, 29 Aug 2025 11:00:00 GMT</pubDate>
<description>IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Friday, September 5, 2025, at 9:10 a.m. ET (6:10 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company’s website under Events</description>
</item>
<item>
<title>Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-reports-second-quarter-202000244</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-pharmaceuticals-reports-second-quarter-202000244</guid>
<pubDate>Thu, 14 Aug 2025 20:20:00 GMT</pubDate>
<description>Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025 Cash, cash equivalents and short-term investments of $107.6 million as of June 30, 2025 IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its second quar</description>
</item>
<item>
<title>Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation</title>
<link>https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-presents-updated-data-ongoing-200100790</link>
<guid isPermaLink="true">https://6ix.com/company/eledon-pharmaceuticals-inc/news/eledon-presents-updated-data-ongoing-200100790</guid>
<pubDate>Wed, 06 Aug 2025 20:01:00 GMT</pubDate>
<description>Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may improve 5-year graft survival vs. current standard of care Tegoprubart continues to be well tolerated with no cases of death, graft loss, drug related tremor, or new-onset diabetes Conference call to be held today at 4:30 p.m. ET IRVINE, Calif</description>
</item>
</channel>
</rss>